DNA Vaccines against Protozoan Parasites:  Advances and Challenges

Dumonteil, Eric

doi:https://doi.org/10.1155/2007/90520

BioMed Research International

On this page

Abstract References Copyright Related Articles

Special Issue

Immunology and Molecular Biology of Protozoan Infections

View this Special Issue

Review Article | Open Access

Volume 2007 | Article ID 090520 | https://doi.org/10.1155/2007/90520

DNA Vaccines against Protozoan Parasites: Advances and Challenges

Eric Dumonteil¹

Academic Editor: Ali Ouaissi

Received08 Dec 2006

Accepted21 Mar 2007

Published21 Jun 2007

Abstract

Over the past 15 years, DNA vaccines have gone from a scientific curiosity to one of the most dynamic research field and may offer new alternatives for the control of parasitic diseases such as leishmaniasis and Chagas disease. We review here some of the advances and challenges for the development of DNA vaccines against these diseases. Many studies have validated the concept of using DNA vaccines for both protection and therapy against these protozoan parasites in a variety of mouse models. The challenge now is to translate what has been achieved in these models into veterinary or human vaccines of comparable efficacy. Also, genome-mining and new antigen discovery strategies may provide new tools for a more rational search of novel vaccine candidates.

References

M. A. Liu, B. Wahren, and G. B. K. Hedestam, “DNA vaccines: recent developments and future possibilities,” Human Gene Therapy, vol. 17, no. 11, pp. 1051–1061, 2006.
View at: Publisher Site | Google Scholar
H. W. Murray, J. D. Berman, C. R. Davies, and N. G. Saravia, “Advances in leishmaniasis,” The Lancet, vol. 366, no. 9496, pp. 1561–1577, 2005.
View at: Publisher Site | Google Scholar
J. Alexander and K. Bryson, “T helper (h)1/Th2 and Leishmania: paradox rather than paradigm,” Immunology Letters, vol. 99, no. 1, pp. 17–23, 2005.
View at: Publisher Site | Google Scholar
D. McMahon-Pratt and J. Alexander, “Does the Leishmania major paradigm of pathogenesis and protection hold for New World cutaneous leishmaniases or the visceral disease?” Immunological Reviews, vol. 201, no. 1, pp. 206–224, 2004.
View at: Publisher Site | Google Scholar
J. A. Castro, M. M. de Mecca, and L. C. Bartel, “Toxic side effects of drugs used to treat Chagas' disease (American trypanosomiasis),” Human and Experimental Toxicology, vol. 25, no. 8, pp. 471–479, 2006.
View at: Publisher Site | Google Scholar
R. L. Sheets, J. Stein, T. S. Manetz et al., “Biodistribution of DNA plasmid vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile virus is similar, without integration, despite differing plasmid backbones or gene inserts,” Toxicological Sciences, vol. 91, no. 2, pp. 610–619, 2006.
View at: Publisher Site | Google Scholar
R. L. Sheets, J. Stein, T. S. Manetz et al., “Toxicological safety evaluation of DNA plasmid vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile virus is similar despite differing plasmid backbones or gene-inserts,” Toxicological Sciences, vol. 91, no. 2, pp. 620–630, 2006.
View at: Publisher Site | Google Scholar
J. Louis, H. Himmelrich, C. Parra-Lopez, F. Tacchini-Cottier, and P. Launois, “Regulation of protective immunity against Leishmania major in mice,” Current Opinion in Immunology, vol. 10, no. 4, pp. 459–464, 1998.
View at: Publisher Site | Google Scholar
S. A. Miles, S. M. Conrad, R. G. Alves, S. M. B. Jeronimo, and D. M. Mosser, “A role for IgG immune complexes during infection with the intracellular pathogen Leishmania,” The Journal of Experimental Medicine, vol. 201, no. 5, pp. 747–754, 2005.
View at: Publisher Site | Google Scholar
S. Stäger, J. Alexander, A. C. Kirby et al., “Natural antibodies and complement are endogenous adjuvants for vaccine-induced $CD 8^{+}$ T-cell responses,” Nature Medicine, vol. 9, no. 10, pp. 1287–1292, 2003.
View at: Publisher Site | Google Scholar
F. Woelbing, S. L. Kostka, K. Moelle et al., “Uptake of Leishmania major by dendritic cells is mediated by Fc $?$ receptors and facilitates acquisition of protective immunity,” The Journal of Experimental Medicine, vol. 203, no. 1, pp. 177–188, 2006.
View at: Publisher Site | Google Scholar
C. Bogdan and M. Röllinghoff, “The immune response to Leishmania: mechanisms of parasite control and evasion,” International Journal for Parasitology, vol. 28, no. 1, pp. 121–134, 1998.
View at: Publisher Site | Google Scholar
S. Méndez, Y. Belkaid, R. A. Seder, and D. Sacks, “Optimization of DNA vaccination against cutaneous leishmaniasis,” Vaccine, vol. 20, no. 31-32, pp. 3702–3708, 2002.
View at: Publisher Site | Google Scholar
P. S. Walker, “American Academy of Dermatology 1997 Awards for Young Investigators in Dermatology. Direct targeting of skin with DNA vaccines for genetic immunization against Leishmania in a murine model,” Journal of the American Academy of Dermatology, vol. 37, no. 5, part 1, pp. 776–777, 1997.
View at: Google Scholar
P. S. Walker, T. Scharton-Kersten, E. D. Rowton et al., “Genetic immunization with glycoprotein 63 cDNA results in a helper T cell type 1 immune response and protection in a murine model of leishmaniasis,” Human Gene Therapy, vol. 9, no. 13, pp. 1899–1907, 1998.
View at: Google Scholar
D. Xu and F. Y. Liew, “Genetic vaccination against leishmaniasis,” Vaccine, vol. 12, no. 16, pp. 1534–1536, 1994.
View at: Publisher Site | Google Scholar
D. Xu and F. Y. Liew, “Protection against leishmaniasis by injection of DNA encoding a major surface glycoprotein, gp63, of L. major,” Immunology, vol. 84, no. 2, pp. 173–176, 1995.
View at: Google Scholar
S. Gurunathan, D. L. Sacks, D. R. Brown et al., “Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major,” The Journal of Experimental Medicine, vol. 186, no. 7, pp. 1137–1147, 1997.
View at: Publisher Site | Google Scholar
S. Gurunathan, C. Prussin, D. L. Sacks, and R. A. Seder, “Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection,” Nature Medicine, vol. 4, no. 12, pp. 1409–1415, 1998.
View at: Publisher Site | Google Scholar
S. Gurunathan, L. Stobie, C. Prussin et al., “Requirements for the maintenance of Th1 immunity in vivo following DNA vaccination: a potential immunoregulatory role for $CD 8^{+}$ T cells,” The Journal of Immunology, vol. 165, no. 2, pp. 915–924, 2000.
View at: Google Scholar
L. Stobie, S. Gurunathan, C. Prussin et al., “The role of antigen and IL-12 in sustaining Th1 memory cells in vivo: IL-12 is required to maintain memory/effector Th1 cells sufficient to mediate protection to an infectious parasite challenge,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 15, pp. 8427–8432, 2000.
View at: Publisher Site | Google Scholar
S. Iborra, M. Soto, J. Carrión, C. Alonso, and J. M. Requena, “Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis,” Vaccine, vol. 22, no. 29-30, pp. 3865–3876, 2004.
View at: Publisher Site | Google Scholar
E. Dumonteil, M. J. Ramirez-Sierra, J. Escobedo-Ortegonr, and M. R. García-Miss, “DNA vaccines induce partial protection against Leishmania mexicana,” Vaccine, vol. 21, no. 17-18, pp. 2161–2168, 2003.
View at: Publisher Site | Google Scholar
E. A. Marques-da-Silva, E. A. F. Coelho, D. C. O. Gomes et al., “Intramuscular immunization with p36(LACK) DNA vaccine induces IFN- $?$ production but does not protect BALB/c mice against Leishmania chagasi intravenous challenge,” Parasitology Research, vol. 98, no. 1, pp. 67–74, 2005.
View at: Publisher Site | Google Scholar
P. C. Melby, J. Yang, W. Zhao, L. E. Perez, and J. Cheng, “Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis,” Infection and Immunity, vol. 69, no. 8, pp. 4719–4725, 2001.
View at: Publisher Site | Google Scholar
R. M. Gonzalo, G. del Real, J. R. Rodriguez et al., “A heterologous prime-boost regime using DNA and recombinant vaccinia virus expressing the Leishmania infantum P36/LACK antigen protects BALB/c mice from cutaneous leishmaniasis,” Vaccine, vol. 20, no. 7-8, pp. 1226–1231, 2002.
View at: Publisher Site | Google Scholar
E. Tapia, E. Pérez-Jiménez, L. López-Fuertes, R. Gonzalo, M. M. Gherardi, and M. Esteban, “The combination of DNA vectors expressing IL-12 + IL-18 elicits high protective immune response against cutaneous leishmaniasis after priming with DNA-p36/LACK and the cytokines, followed by a booster with a vaccinia virus recombinant expressing p36/LACK,” Microbes and Infection, vol. 5, no. 2, pp. 73–84, 2003.
View at: Publisher Site | Google Scholar
E. Pérez-Jiménez, G. Kochan, M. M. Gherardi, and M. Esteban, “MVA-LACK as a safe and efficient vector for vaccination against leishmaniasis,” Microbes and Infection, vol. 8, no. 3, pp. 810–822, 2006.
View at: Publisher Site | Google Scholar
B. Dondji, E. Pérez-Jimenez, K. Goldsmith-Pestana, M. Esteban, and D. McMahon-Pratt, “Heterologous prime-boost vaccination with the LACK antigen protects against murine visceral leishmaniasis,” Infection and Immunity, vol. 73, no. 8, pp. 5286–5289, 2005.
View at: Publisher Site | Google Scholar
C. B. Stober, U. G. Lange, M. T. M. Roberts, A. Alcami, and J. M. Blackwell, “Heterologous priming-boosting with DNA and modified vaccinia virus Ankara expressing tryparedoxin peroxidase promotes long-term memory against Leishmania major in susceptible BALB/c mice,” Infection and Immunity, vol. 75, no. 2, pp. 852–860, 2007.
View at: Publisher Site | Google Scholar
S. Iborra, M. Soto, J. Carrión et al., “The Leishmania infantum acidic ribosomal protein P0 administered as a DNA vaccine confers protective immunity to Leishmania major infection in BALB/c mice,” Infection and Immunity, vol. 71, no. 11, pp. 6562–6572, 2003.
View at: Publisher Site | Google Scholar
S. Rafati, F. Ghaemimanesh, and F. Zahedifard, “Comparison of potential protection induced by three vaccination strategies (DNA/DNA, Protein/Protein and DNA/Protein) against Leishmania major infection using Signal Peptidase type I in BALB/c mice,” Vaccine, vol. 24, no. 16, pp. 3290–3297, 2006.
View at: Publisher Site | Google Scholar
A. Campos-Neto, J. R. Webb, K. Greeson, R. N. Coler, Y. A.W. Skeiky, and S. G. Reed, “Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice,” Infection and Immunity, vol. 70, no. 6, pp. 2828–2836, 2002.
View at: Publisher Site | Google Scholar
S. Rafati, A.-H. Salmanian, T. Taheri, M. Vafa, and N. Fasel, “A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major,” Vaccine, vol. 19, no. 25-26, pp. 3369–3375, 2001.
View at: Publisher Site | Google Scholar
A. Sjölander, T. M. Baldwin, J. M. Curtis, and E. Handman, “Induction of a Th1 immune response and simultaneous lack of activation of a Th2 response are required for generation of immunity to leishmaniasis,” The Journal of Immunology, vol. 160, no. 8, pp. 3949–3957, 1998.
View at: Google Scholar
S. B. H. Ahmed, C. Bahloul, C. Robbana, S. Askri, and K. Dellagi, “A comparative evaluation of different DNA vaccine candidates against experimental murine leishmaniasis due to L. major,” Vaccine, vol. 22, no. 13-14, pp. 1631–1639, 2004.
View at: Publisher Site | Google Scholar
C. H. C. Serezani, A. R. Franco, M. Wajc et al., “Evaluation of the murine immune response to Leishmania meta 1 antigen delivered as recombinant protein or DNA vaccine,” Vaccine, vol. 20, no. 31-32, pp. 3755–3763, 2002.
View at: Publisher Site | Google Scholar
K. Campbell, H. Diao, J. Ji, and L. Soong, “DNA immunization with the gene encoding P4 nuclease of Leishmania amazonensis protects mice against cutaneous leishmaniasis,” Infection and Immunity, vol. 71, no. 11, pp. 6270–6278, 2003.
View at: Publisher Site | Google Scholar
E. Dumonteil, F. Andrade-Narvarez, J. Escobedo-Ortegon et al., “Comparative study of DNA vaccines encoding various antigens against Leishmania mexicana,” Developments in Biologicals, vol. 104, pp. 135–141, 2000.
View at: Google Scholar
I. Aguilar-Be, R. da Silva Zardo, E. Paraguai de Souza et al., “Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis,” Infection and Immunity, vol. 73, no. 2, pp. 812–819, 2005.
View at: Publisher Site | Google Scholar
M. Rosado-Vallado, M. Mut-Martin, M. R. García-Miss, and E. Dumonteil, “Aluminium phosphate potentiates the efficacy of DNA vaccines against Leishmania mexicana,” Vaccine, vol. 23, no. 46-47, pp. 5372–5379, 2005.
View at: Publisher Site | Google Scholar
S. Rafati, F. Zahedifard, and F. Nazgouee, “Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis,” Vaccine, vol. 24, no. 12, pp. 2169–2175, 2006.
View at: Publisher Site | Google Scholar
B. Sukumaran, P. Tewary, S. Saxena, and R. Madhubala, “Vaccination with DNA encoding ORFF antigen confers protective immunity in mice infected with Leishmania donovani,” Vaccine, vol. 21, no. 11-12, pp. 1292–1299, 2003.
View at: Publisher Site | Google Scholar
A. Sjölander, T. M. Baldwin, J. M. Curtis, K. L. Bengtsson, and E. Handman, “Vaccination with recombinant Parasite Surface Antigen 2 from Leishmania major induces a Th1 type of immune response but does not protect against infection,” Vaccine, vol. 16, no. 20, pp. 2077–2084, 1998.
View at: Publisher Site | Google Scholar
S. Méndez, S. Gurunathan, S. Kamhawi et al., “The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge,” The Journal of Immunology, vol. 166, no. 8, pp. 5122–5128, 2001.
View at: Google Scholar
M. A. Barry, W. C. Lai, and S. A. Johnston, “Protection against mycoplasma infection using expression-library immunization,” Nature, vol. 377, no. 6550, pp. 632–635, 1995.
View at: Publisher Site | Google Scholar
D. Piedrafita, D. Xu, D. Hunter, R. A. Harrison, and F. Y. Liew, “Protective immune responses induced by vaccination with an expression genomic library of Leishmania major,” The Journal of Immunology, vol. 163, no. 3, pp. 1467–1472, 1999.
View at: Google Scholar
P. C. Melby, G. B. Ogden, H. A. Flores et al., “Identification of vaccine candidates for experimental visceral leishmaniasis by immunization with sequential fractions of a cDNA expression library,” Infection and Immunity, vol. 68, no. 10, pp. 5595–5602, 2000.
View at: Publisher Site | Google Scholar
A. C. Ivens, C. S. Peacock, E. A. Worthey et al., “The genome of the kinetoplastid parasite, Leishmania major,” Science, vol. 309, no. 5733, pp. 436–442, 2005.
View at: Publisher Site | Google Scholar
C. B. Stober, “From genomes to vaccines for leishmaniasis,” Methods in Molecular Biology, vol. 270, pp. 423–438, 2004.
View at: Google Scholar
C. B. Stober, U. G. Lange, M. T. M. Roberts et al., “From genome to vaccines for leishmaniasis: screening 100 novel vaccine candidates against murine Leishmania major infection,” Vaccine, vol. 24, no. 14, pp. 2602–2616, 2006.
View at: Publisher Site | Google Scholar
N. G. Saravia, M. H. Hazbón, Y. Osorio et al., “Protective immunogenicity of the paraflagellar rod protein 2 of Leishmania mexicana,” Vaccine, vol. 23, no. 8, pp. 984–995, 2005.
View at: Publisher Site | Google Scholar
R. Basu, S. Bhaumik, J. M. Basu, K. Naskar, T. De, and S. Roy, “Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis,” The Journal of Immunology, vol. 174, no. 11, pp. 7160–7171, 2005.
View at: Google Scholar
K. Fragaki, I. Suffia, B. Ferrua, D. Rousseau, Y. Le Fichoux, and J. Kubar, “Immunisation with DNA encoding Leishmania infantum protein papLe22 decreases the frequency of parasitemic episodes in infected hamsters,” Vaccine, vol. 19, no. 13-14, pp. 1701–1709, 2001.
View at: Publisher Site | Google Scholar
M. J. Ramiro, J. J. Zárate, T. Hanke et al., “Protection in dogs against visceral leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime-boost regime using DNA and vaccinia recombinant vectors expressing LACK,” Vaccine, vol. 21, no. 19-20, pp. 2474–2484, 2003.
View at: Publisher Site | Google Scholar
O. A. Saldarriaga, B. L. Travi, W. Park, L. E. Perez, and P. C. Melby, “Immunogenicity of a multicomponent DNA vaccine against visceral leishmaniasis in dogs,” Vaccine, vol. 24, no. 11, pp. 1928–1940, 2006.
View at: Publisher Site | Google Scholar
S. Rafati, A. Nakhaee, T. Taheri et al., “Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum,” Vaccine, vol. 23, no. 28, pp. 3716–3725, 2005.
View at: Publisher Site | Google Scholar
B. Autran, G. Carcelain, B. Combadiere, and P. Debre, “Therapeutic vaccines for chronic infections,” Science, vol. 305, no. 5681, pp. 205–208, 2004.
View at: Publisher Site | Google Scholar
E. Handman, A. H. Noormohammadi, J. M. Curtis, T. Baldwin, and A. Sjölander, “Therapy of murine cutaneous leishmaniasis by DNA vaccination,” Vaccine, vol. 18, no. 26, pp. 3011–3017, 2000.
View at: Publisher Site | Google Scholar
R. Gamboa-León, E. Paraguai de Souza, G. P. Borja-Cabrera et al., “Immunotherapy against visceral leishmaniasis with the nucleoside hydrolase-DNA vaccine of Leishmania donovani,” Vaccine, vol. 24, no. 22, pp. 4863–4873, 2006.
View at: Publisher Site | Google Scholar
J. R. Espinoza, A. C. Skinner, C. R. Davies et al., “Extensive polymorphism at the Gp63 locus in field isolates of Leishmania peruviana,” Molecular and Biochemical Parasitology, vol. 72, no. 1-2, pp. 203–213, 1995.
View at: Publisher Site | Google Scholar
S. Guerbouj, K. Victoir, I. Guizani et al., “Gp63 gene polymorphism and population structure of Leishmania donovani complex: influence of the host selection pressure?” Parasitology, vol. 122, no. 1, pp. 25–35, 2001.
View at: Publisher Site | Google Scholar
F. Alvarez-Valin, J. F. Tort, and G. Bernardi, “Nonrandom spatial distribution of synonymous substitutions in the GP63 gene from Leishmania,” Genetics, vol. 155, no. 4, pp. 1683–1692, 2000.
View at: Google Scholar
S. Guerbouj, I. Guizani, K. Victoir, D. Le Ray, and J.-C. Dujardin, “Parasite candidate vaccines: a warning from polymorphic Leishmania populations,” Parasitology Today, vol. 16, no. 6, pp. 265–266, 2000.
View at: Publisher Site | Google Scholar
D. A. Fitzpatrick, C. J. Creevey, and J. O. McInerney, “Evidence of positive Darwinian selection in putative meningococcal vaccine antigens,” Journal of Molecular Evolution, vol. 61, no. 1, pp. 90–98, 2005.
View at: Publisher Site | Google Scholar
C. Kumkhaek, K. Phra-Ek, L. Rénia et al., “Are extensive T cell epitope polymorphisms in the Plasmodium falciparum circumsporozoite antigen, a leading sporozoite vaccine candidate, selected by immune pressure?” The Journal of Immunology, vol. 175, no. 6, pp. 3935–3939, 2005.
View at: Google Scholar
E. F. Pinto, R. O. Pinheiro, A. Rayol, V. Larraga, and B. Rossi-Bergmann, “Intranasal vaccination against cutaneous leishmaniasis with a particulated leishmanial antigen or DNA encoding LACK,” Infection and Immunity, vol. 72, no. 8, pp. 4521–4527, 2004.
View at: Publisher Site | Google Scholar
Y. Belkaid, S. Kamhawi, G. Modi et al., “Development of a natural model of cutaneous leishmaniasis: powerful effects of vector saliva and saliva preexposure on the long-term outcome of Leishmania major infection in the mouse ear dermis,” The Journal of Experimental Medicine, vol. 188, no. 10, pp. 1941–1953, 1998.
View at: Publisher Site | Google Scholar
M. L. Mbow, J. A. Bleyenberg, L. R. Hall, and R. G. Titus, “Phlebotomus papatasi sand fly salivary gland lysate down-regulates a Th1, but up-regulates a Th2, response in mice infected with Leishmania major,” The Journal of Immunology, vol. 161, no. 10, pp. 5571–5577, 1998.
View at: Google Scholar
S. Kamhawi, Y. Belkaid, G. Modi, E. Rowton, and D. Sacks, “Protection against cutaneous leishmaniasis resulting from bites of uninfected sand flies,” Science, vol. 290, no. 5495, pp. 1351–1354, 2000.
View at: Publisher Site | Google Scholar
R. V. Morris, C. B. Shoemaker, J. R. David, G. C. Lanzaro, and R. G. Titus, “Sandfly maxadilan exacerbates infection with Leishmania major and vaccinating against it protects against L. major infection,” The Journal of Immunology, vol. 167, no. 9, pp. 5226–5230, 2001.
View at: Google Scholar
J. G. Valenzuela, Y. Belkaid, M. K. Garfield et al., “Toward a defined anti-Leishmania vaccine targeting vector antigens: characterization of a protective salivary protein,” The Journal of Experimental Medicine, vol. 194, no. 3, pp. 331–342, 2001.
View at: Publisher Site | Google Scholar
J. M. Anderson, F. Oliveira, S. Kamhawi et al., “Comparative salivary gland transcriptomics of sandfly vectors of visceral leishmaniasis,” BMC Genomics, vol. 7, p. 52, 2006.
View at: Publisher Site | Google Scholar
J. G. Valenzuela, M. Garfield, E. D. Rowton, and V. M. Pham, “Identification of the most abundant secreted proteins from the salivary glands of the sand fly Lutzomyia longipalpis, vector of Leishmania chagasi,” The Journal of Experimental Biology, vol. 207, no. 21, pp. 3717–3729, 2004.
View at: Publisher Site | Google Scholar
D.-E. A. Elnaiem, C. Meneses, M. Slotman, and G. C. Lanzaro, “Genetic variation in the sand fly salivary protein, SP-15, a potential vaccine candidate against Leishmania major,” Insect Molecular Biology, vol. 14, no. 2, pp. 145–150, 2005.
View at: Publisher Site | Google Scholar
R. S. Milleron, J.-P. Mutebi, S. Valle et al., “Antigenic diversity in maxadilan, a salivary protein from the sand fly vector of American visceral leishmaniasis,” American Journal of Tropical Medicine and Hygiene, vol. 70, no. 3, pp. 286–293, 2004.
View at: Google Scholar
E. M. Saraiva, A. de Figueiredo Barbosa, F. N. Santos et al., “The FML-vaccine $({Leishmune}^{®})$ against canine visceral leishmaniasis: a transmission blocking vaccine,” Vaccine, vol. 24, no. 13, pp. 2423–2431, 2006.
View at: Publisher Site | Google Scholar
N. Gironés, H. Cuervo, and M. Fresno, “Trypanosoma cruzi-induced molecular mimicry and Chagas' disease,” Current Topics in Microbiology and Immunology, vol. 296, pp. 89–123, 2005.
View at: Google Scholar
R. L. Tarleton, “Parasite persistence in the aetiology of Chagas disease,” International Journal for Parasitology, vol. 31, no. 5-6, pp. 549–553, 2001.
View at: Publisher Site | Google Scholar
V. Bhatia and N. Garg, “Current status and future prospects for a vaccine against American trypanosomiasis,” Expert Review of Vaccines, vol. 4, no. 6, pp. 867–880, 2005.
View at: Publisher Site | Google Scholar
F. Kierszenbaum, “Where do we stand on the autoimmunity hypothesis of Chagas disease?” Trends in Parasitology, vol. 21, no. 11, pp. 513–516, 2005.
View at: Publisher Site | Google Scholar
D. F. Hoft, A. R. Schnapp, C. S. Eickhoff, and S. T. Roodman, “Involvement of $CD 4^{+}$ Th1 cells in systemic immunity protective against primary and secondary challenges with Trypanosoma cruzi,” Infection and Immunity, vol. 68, no. 1, pp. 197–204, 2000.
View at: Google Scholar
D. Martin and R. Tarleton, “Generation, specificity, and function of $CD 8^{+}$ T cells in Trypanosoma cruzi infection,” Immunological Reviews, vol. 201, no. 1, pp. 304–317, 2004.
View at: Publisher Site | Google Scholar
M. M. Rodrigues, M. Ribeirão, V. Pereira-Chioccola, L. Renia, and F. Costa, “Predominance of CD4 Th1 and CD8 Tc1 cells revealed by characterization of the cellular immune response generated by immunization with a DNA vaccine containing a Trypanosoma cruzi gene,” Infection and Immunity, vol. 67, no. 8, pp. 3855–3863, 1999.
View at: Google Scholar
M. M. Rodrigues, S. B. Boscardin, J. R. Vasconcelos, M. I. Hiyane, G. Salay, and I. S. Soares, “Importance of CD8 T cell-mediated immune response during intracellular parasitic infections and its implications for the development of effective vaccines,” Anais da Academia Brasileira de Ciências, vol. 75, no. 4, pp. 443–468, 2003.
View at: Google Scholar
F. Costa, G. Franchin, V. L. Pereira-Chioccola, M. Ribeirão, S. Schenkman, and M. M. Rodrigues, “Immunization with a plasmid DNA containing the gene of trans-sialidase reduces Trypanosoma cruzi infection in mice,” Vaccine, vol. 16, no. 8, pp. 768–774, 1998.
View at: Publisher Site | Google Scholar
N. Garg and R. L. Tarleton, “Genetic immunization elicits antigen-specific protective immune responses and decreases disease severity in Trypanosoma cruzi infection,” Infection and Immunity, vol. 70, no. 10, pp. 5547–5555, 2002.
View at: Publisher Site | Google Scholar
B. Wizel, M. Nunes, and R. L. Tarleton, “Identification of Trypanosoma cruzi trans-sialidase family members as targets of protective $CD 8^{+}$ TC1 responses,” The Journal of Immunology, vol. 159, no. 12, pp. 6120–6130, 1997.
View at: Google Scholar
F. Costa, V. L. Pereira-Chioccola, M. Ribeirão, S. Schenkman, and M. M. Rodrigues, “Trans-sialidase delivered as a naked DNA vaccine elicits an immunological response similar to a Trypanosoma cruzi infection,” Brazilian Journal of Medical and Biological Research, vol. 32, no. 2, pp. 235–239, 1999.
View at: Publisher Site | Google Scholar
V. L. Pereira-Chioccola, F. Costa, M. Ribeirão et al., “Comparison of antibody and protective immune responses against Trypanosoma cruzi infection elicited by immunization with a parasite antigen delivered as naked DNA or recombinant protein,” Parasite Immunology, vol. 21, no. 2, pp. 103–110, 1999.
View at: Publisher Site | Google Scholar
B. Wizel, N. Garg, and R. L. Tarleton, “Vaccination with trypomastigote surface antigen 1-encoding plasmid DNA confers protection against lethal Trypanosoma cruzi infection,” Infection and Immunity, vol. 66, no. 11, pp. 5073–5081, 1998.
View at: Google Scholar
G. A. García, M. R. Arnaiz, S. A. Laucella et al., “Immunological and pathological responses in BALB/c mice induced by genetic administration of $T c 13$ Tul antigen of Trypanosoma cruzi,” Parasitology, vol. 132, no. 6, pp. 855–866, 2006.
View at: Publisher Site | Google Scholar
S. B. Boscardin, S. S. Kinoshita, A. E. Fujimura, and M. M. Rodrigues, “Immunization with cDNA expressed by amastigotes of Trypanosoma cruzi elicits protective immune response against experimental infection,” Infection and Immunity, vol. 71, no. 5, pp. 2744–2757, 2003.
View at: Publisher Site | Google Scholar
M. Katae, Y. Miyahira, K. Takeda et al., “Coadministration of an interleukin-12 gene and a Trypanosoma cruzi gene improves vaccine efficacy,” Infection and Immunity, vol. 70, no. 9, pp. 4833–4840, 2002.
View at: Publisher Site | Google Scholar
Y. Miyahira, M. Katae, K. Takeda et al., “Activation of natural killer T cells by $a$ -galactosylceramide impairs DNA vaccine-induced protective immunity against Trypanosoma cruzi,” Infection and Immunity, vol. 71, no. 3, pp. 1234–1241, 2003.
View at: Publisher Site | Google Scholar
B. H. Fralish and R. L. Tarleton, “Genetic immunization with LYT1 or a pool of trans-sialidase genes protects mice from lethal Trypanosoma cruzi infection,” Vaccine, vol. 21, no. 21-22, pp. 3070–3080, 2003.
View at: Publisher Site | Google Scholar
J. R. Vasconcelos, M. I. Hiyane, C. R. F. Marinho et al., “Protective immunity against Trypanosoma cruzi infection in a highly susceptible mouse strain after vaccination with genes encoding the amastigote surface protein-2 and trans-sialidase,” Human Gene Therapy, vol. 15, no. 9, pp. 878–886, 2004.
View at: Publisher Site | Google Scholar
P. Sepulveda, M. Hontebeyrie, P. Liegeard, A. Mascilli, and K. A. Norris, “DNA-based immunization with Trypanosoma cruzi complement regulatory protein elicits complement lytic antibodies and confers protection against Trypanosoma cruzi infection,” Infection and Immunity, vol. 68, no. 9, pp. 4986–4991, 2000.
View at: Publisher Site | Google Scholar
A. R. Schnapp, C. S. Eickhoff, J. Scharfstein, and D. F. Hoft, “Induction of B- and T-cell responses to cruzipain in the murine model of Trypanosoma cruzi infection,” Microbes and Infection, vol. 4, no. 8, pp. 805–813, 2002.
View at: Publisher Site | Google Scholar
L. Planelles, M. C. Thomas, C. Alonso, and M. C. López, “DNA immunization with Trypanosoma cruzi HSP70 fused to the KMP11 protein elicits a cytotoxic and humoral immune response against the antigen and leads to protection,” Infection and Immunity, vol. 69, no. 10, pp. 6558–6563, 2001.
View at: Publisher Site | Google Scholar
F. Tzelepis, B. C. G. de Alencar, M. L. O. Penido, R. T. Gazzinelli, P. M. Persechini, and M. M. Rodrigues, “Distinct kinetics of effector $CD 8^{+}$ cytotoxic T cells after infection with Trypanosoma cruzi in naïve or vaccinated mice,” Infection and Immunity, vol. 74, no. 4, pp. 2477–2481, 2006.
View at: Publisher Site | Google Scholar
A. E. Fujimura, S. S. Kinoshita, V. L. Pereira-Chioccola, and M. M. Rodrigues, “DNA sequences encoding ${CD4}^{+}$ and ${CD8}^{+}$ T-cell epitopes are important for efficient protective immunity induced by DNA vaccination with a Trypanosoma cruzi gene,” Infection and Immunity, vol. 69, no. 9, pp. 5477–5486, 2001.
View at: Publisher Site | Google Scholar
J. R. Vasconcelos, S. B. Boscardin, M. I. Hiyane, S. S. Kinoshita, A. E. Fujimura, and M. M. Rodrigues, “A DNA-priming protein-boosting regimen significantly improves type 1 immune response but not protective immunity to Trypanosoma cruzi infection in a highly susceptible mouse strain,” Immunology and Cell Biology, vol. 81, no. 2, pp. 121–129, 2003.
View at: Publisher Site | Google Scholar
E. Dumonteil, J. Escobedo-Ortegon, N. Reyes-Rodriguez, A. Arjona-Torres, and M. J. Ramirez-Sierra, “Immunotherapy of Trypanosoma cruzi infection with DNA vaccines in mice,” Infection and Immunity, vol. 72, no. 1, pp. 46–53, 2004.
View at: Publisher Site | Google Scholar
G. Sanchez-Burgos, G. Mezquita-Vega, J. Escobedo-Ortegon et al., “Comparative efficacy of DNA vaccines encoding various Trypanosoma cruzi antigens,” FEMS Immunology and Medical Microbiology,(Online Early Articles) Doi:10.1111/j.1574-695X.2007.00251.X, 2007.
View at: Google Scholar
H. Zapata-Estrella, C. Hummel-Newell, G. Sanchez-Burgos et al., “Control of Trypanosoma cruzi infection and changes in T-cell populations induced by a therapeutic DNA vaccine in mice,” Immunology Letters, vol. 103, no. 2, pp. 186–191, 2006.
View at: Publisher Site | Google Scholar
E. Alberti, A. Acosta, M. E. Sarmiento et al., “Specific cellular and humoral immune response in Balb/c mice immunised with an expression genomic library of Trypanosoma cruzi,” Vaccine, vol. 16, no. 6, pp. 608–612, 1998.
View at: Publisher Site | Google Scholar
V. Bhatia, M. Sinha, B. Luxon, and N. Garg, “Utility of the Trypanosoma cruzi sequence database for identification of potential vaccine candidates by in silico and in vitro screening,” Infection and Immunity, vol. 72, no. 11, pp. 6245–6254, 2004.
View at: Publisher Site | Google Scholar
S. Manoj, L. A. Babiuk, and S. van Drunen Littel-van den Hurk, “Approaches to enhance the efficacy of DNA vaccines,” Critical Reviews in Clinical Laboratory Sciences, vol. 41, no. 1, pp. 1–39, 2004.
View at: Publisher Site | Google Scholar
M. Moutaftsi, B. Peters, V. Pasquetto et al., “A consensus epitope prediction approach identifies the breadth of murine $T_{CD 8 +}$ -cell responses to vaccinia virus,” Nature Biotechnology, vol. 24, no. 7, pp. 817–819, 2006.
View at: Publisher Site | Google Scholar

Copyright

Copyright © 2007 Eric Dumonteil. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation Order printed copies

Views

1142

Downloads

1841

Citations